In this session, Elena Stoyanova, PhD (Touchlight) introduces mbDNA™ (Megabulb DNA), a novel single-stranded circular DNA template featuring a customizable stem region and fully user-defined sequence. Chesney Michels, PhD (ElevateBio) highlights how mbDNA™ was applied in combination with Life Edit’s LEG14 nuclease, a proprietary RNA-guided nuclease, to enable efficient, targeted genome editing. Together, these technologies were used to knock out the endogenous TCR and insert an exogenous TCR targeting the NYESO-1 antigen. HDR-mediated knock-in with two distinct circular donor templates—MegabulbDNA™ (circular, single-stranded DNA) and Plasmid (next generation circular double stranded)—facilitated stable genome integration, with mbDNA™ yielding a 2-fold increase in anti-NYESO-1 TCR T cells.

Discover how this nuclease-driven, non-viral approach offers a scalable, versatile, and precise solution for next-generation T cell therapies.

Download the webinar to learn:

• The limitations of viral transduction and explore how non-viral methods such as CRISPR-based genome editing are addressing challenges in cost, safety, and scalability for T cell engineering
• mbDNA™, a novel circular single-stranded DNA template, and how its customizable design enables precise and efficient genome editing in combination with proprietary nucleases
• Gain insights into a real-world application of mbDNA™ and LEG14 nuclease for targeted TCR knock-in, including comparative performance data with Plasmid (next generation circular double stranded) and the implications for next-generation T cell therapies